Nexentis Technologies Swaps KPMG Israel for Deloitte Israel Amid Going Concern Warning
NXTS sits 35% above its 52-week low of $1.43.
Summary
Nexentis Technologies replaced its independent auditor, dismissing KPMG Israel and engaging Deloitte Israel, effective August 6, 2026. The change occurs against a backdrop of going concern warnings and financial distress.
Key Events · Corporate Governance and Compliance · NXTS
-
Auditor Dismissal
Effective August 6, 2026, KPMG Israel was dismissed as independent auditor. While no disagreements were reported, prior audit reports included a going concern paragraph.
-
New Auditor Appointed
Deloitte Israel has been engaged to audit the fiscal year 2026 financial statements, with no prior consultations on accounting or auditing matters.
-
Going Concern Context
Recurring losses and a net capital deficiency raise substantial doubt about the company's ability to continue as a going concern.
-
Recent Financial Distress
This follows multiple dilutive offerings in June 2026 totaling over $4 million, a $6.6 million Q1 net loss, and a reverse stock split in April 2026.
Analysis · NXTS · Life Sciences
On August 6, 2026, Nexentis Technologies dismissed its auditor KPMG Israel and appointed Deloitte Israel. The company faces a going concern warning, recurring losses, and a net capital deficiency. An auditor change at a distressed company often signals potential disagreements over accounting or a search for a more accommodating auditor, though the filing states no disagreements. The move comes after a series of dilutive financings and a recent reverse stock split, adding governance uncertainty.
How filings like this one have moved
In the 30 days to Sep 18, 2026, 35.6% of the 1155 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.41%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NXTS was trading at $1.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8M. The 52-week trading range was $1.43 to $61.25. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.